Sanofi SA (NYSE:SNY) has earned an average rating of “Hold” from the thirteen ratings firms that are presently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $52.50.
SNY has been the topic of a number of recent analyst reports. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, June 21st. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Tuesday, August 6th. Finally, UBS Group upgraded shares of Sanofi from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 14th.
NYSE:SNY traded up $0.71 during mid-day trading on Wednesday, hitting $42.73. 1,117,734 shares of the company’s stock were exchanged, compared to its average volume of 1,238,793. The company has a 50 day simple moving average of $42.20 and a 200-day simple moving average of $42.61. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. Sanofi has a fifty-two week low of $40.00 and a fifty-two week high of $45.62. The firm has a market capitalization of $104.90 billion, a P/E ratio of 13.65, a PEG ratio of 2.41 and a beta of 0.67.
In other news, major shareholder Sanofi purchased 93,750 shares of the company’s stock in a transaction dated Monday, July 22nd. The shares were purchased at an average price of $16.00 per share, for a total transaction of $1,500,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.00% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in the company. Ibex Wealth Advisors purchased a new stake in Sanofi during the second quarter valued at about $25,000. Heritage Wealth Advisors increased its position in shares of Sanofi by 141.2% in the second quarter. Heritage Wealth Advisors now owns 603 shares of the company’s stock worth $26,000 after purchasing an additional 353 shares during the last quarter. Bessemer Group Inc. increased its position in shares of Sanofi by 292.4% in the second quarter. Bessemer Group Inc. now owns 671 shares of the company’s stock worth $29,000 after purchasing an additional 500 shares during the last quarter. Cullen Frost Bankers Inc. bought a new position in shares of Sanofi in the first quarter worth approximately $35,000. Finally, Nkcfo LLC bought a new position in shares of Sanofi in the first quarter worth approximately $35,000. Institutional investors own 7.04% of the company’s stock.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
See Also: Reverse Stock Split
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.